Novo Nordisk A/S Sponsored ADR (NVO)
Novo Nordisk to Pay Up to $1.3 Billion for Nanexa's Drug Delivery Technology
Novo Nordisk agreed to license and develop the technology, which could cut the frequency patients need to inject its obesity and diabetes drugs.
Novo Nordisk: Capital Markets Day Reveals Its Next Growth Engine
At its September 21 Capital Markets Day, Novo Nordisk A/S outlined plans to launch more than five multi-blockbusters by 2030 and deliver over DKK 150 billion in pipeline sales by 2035. CEO Maziar Doustdar said Novo will prioritize asset quality over deal size, with bolt-on acquisitions likely to be the focus while remaining open to larger deals. Meanwhile, in Q2, sales of the Wegovy pill were up 42.6% quarter-on-quarter to about DKK 3.2 billion.
Novo Nordisk open to direct New York listing, CEO says
Novo Nordisk (NYSE:NVO) (NYSE:NVO), the Danish drugmaker, would be open to considering a direct listing of its shares on the New York Stock Exchange, according to chief executive Mike Doustdar. Doustdar told the Financial Times that he could see advantages to such a move, although he clarified that the Danish pharmaceutical company is not currently exploring a change to its US listing structure.
Novo CEO signals M&A opportunities to strengthen drug pipeline
Novo CEO Mike Doustdar told CNBC it's mulling M&A opportunities amid increasing competition. In this article NVO
Novo Nordisk aims to launch more than five blockbuster drugs by 2030, CEO says
Novo Nordisk aims to launch more than five blockbuster drugs by 2030 and to deliver more than 150 billion Danish crowns ($23 billion) in pipeline sales in 2035, its CEO Mike Doustdar said at its Capital Markets Day in London.
Wegovy Maker Novo Nordisk Targets Several New Blockbuster Drugs in Coming Years
Shares in Novo Nordisk fell more than 4% as its CEO laid out plans to launch new blockbuster drugs in the next few years while expanding into further treatment areas.
Wegovy Maker Novo Nordisk Targets Several New Blockbuster Drugs in Coming Years — Update
Shares in Novo Nordisk fell more than 4% as its CEO laid out plans to launch new blockbuster drugs in the next few years while expanding into further treatment areas.
Novo Nordisk stock tumbles as Ozempic maker sets out 2030 goals
Novo Nordisk stock tumbled on Monday as the weight-loss drug manufacturer failed to excite investors hoping for a turnaround.
Novo stock falls as much as 7% despite $23 billion sales target for blockbuster obesity drugs
Novo stock falls as much as 7% despite $23 billion sales target for blockbuster obesity drugs
Novo's Denecimig Gets CHMP Nod for Hemophilia A in the European Union
NVO's denecimig wins a positive European opinion for hemophilia A, with flexible dosing and a potential 2026 launch.
Novo Expands AI Push With Anthropic Deal to Accelerate Drug Discovery
NVO is expanding its AI strategy with Anthropic to tackle drug discovery challenges, boost R&D productivity and develop new medicines faster.
Novo Falls 5% in a Week: How Should Investors Approach the Stock Now?
NVO's 5% drop in a week reflects intensifying GLP-1 competition and semaglutide risks, but its broad pipeline offers potential long-term growth.
